Ceftibuten — Membership Pricing

Other medications in Infections

• Cefuroxime
• Cephalexin
• Chloramphenicol
• Cidofovir
• Clarithromycin
• Colistin
• Dalbavancin
• Darunavir

About Ceftibuten

Ceftibuten is a powerful antibiotic prescribed to combat various bacterial infections. When your doctor prescribes this medication, managing the cost can be a concern. TheDrugClub is dedicated to helping members access their necessary prescriptions, including ceftibuten, at more affordable prices, ensuring you can focus on your health without added financial stress.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ceftibuten is approved for (FDA label)

CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes.

Source: Read the full FDA label on DailyMed. Label effective date: January 12, 2010.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ceftibuten (FDA label)

ADVERSE EVENTS Clinical Trials CEDAX CAPSULES (adult patients) In clinical trials, 1728 adult patients (1092 US and 636 international) were treated with the recommended dose of ceftibuten capsules (400 mg per day). There were no deaths or permanent disabilities thought due to drug toxicity in any of the patients in these studies. Thirty-six of 1728 (2%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or almost certainly related to drug toxicity. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea, vomiting, or nausea. Six of 1728 (0.3%) patients were discontinued due to rash or pruritus thought related to ceftibuten administration.

Source: FDA prescribing information (DailyMed). Set ID: 2dd58c88-142f-41ad-bc31-0a4fff074970. SPL document ID: d1672f05-b1ee-40f9-9b4c-7ba2fad264fc. Label effective date: January 12, 2010. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ceftibuten (FDA label)

CEDAX (ceftibuten) is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Source: FDA prescribing information (DailyMed). Set ID: 2dd58c88-142f-41ad-bc31-0a4fff074970. SPL document ID: d1672f05-b1ee-40f9-9b4c-7ba2fad264fc. Label effective date: January 12, 2010. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ceftibuten (FDA label)

WARNINGS BEFORE THERAPY WITH THE CEDAX PRODUCT IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFTIBUTEN, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO THE CEDAX PRODUCT OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. Pseudomembranous colitis has been reported with nearly all antibacterial agents, including ceftibuten, and may range in severity from mild to life threatening.

Source: FDA prescribing information (DailyMed). Set ID: 2dd58c88-142f-41ad-bc31-0a4fff074970. SPL document ID: d1672f05-b1ee-40f9-9b4c-7ba2fad264fc. Label effective date: January 12, 2010. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ceftibuten (FDA label)

Theophylline Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days. With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg). The pharmacokinetics of theophylline were not altered. The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated. Antacids or H2-receptor antagonists The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers. Each volunteer was administered one 400-mg ceftibuten capsule. A single dose of liquid antacid did not affect the C max or AUC of ceftibuten; however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%. The clinical relevance of these increases is not known.

Source: FDA prescribing information (DailyMed). Set ID: 2dd58c88-142f-41ad-bc31-0a4fff074970. SPL document ID: d1672f05-b1ee-40f9-9b4c-7ba2fad264fc. Label effective date: January 12, 2010. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.